MIF and obesity due to melanocortin 4 receptor deficiency: Given that current anti-obesity drugs are limited by adverse effects, high cost, and the need for long-term administration, rTs-MIF represents a promising new class of anti-obesity candidates that target the immune–metabolic axis.